The Day In Review: Genzyme Corporation Stops Heart Disease Trial
23 Feb 2006
Cell Therapy
February 23, 2006 – Genzyme ended early the enrollment of patients into a Phase II trial of its cell therapy, intended to repair damaged hearts; Nastech Pharma acquired the RNAi technology of Galenea Corporation, including IP licensed from MIT; GTC Biotherapeutics saw 40% of its market value disappear after European authorities recommended against approval of ATryn, an anti-clotting drug; Amgen published positive data from a Phase II trial of its osteoporosis drug, denosumab; Replidyne and Forest Labs reported the FDA has accepted their filing for approval of an antibiotic; and Bioenvision received European recommendation for Evoltra, a therapy for acute lymphobloastic leukemia. The Centient Biotech 200™ was 10 points lower at 3959.90, a drop of .25%. More details...
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.